Cargando…

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment

OBJECTIVE: This prospective cohort, real‐life study aimed to evaluate whether galcanezumab, a monoclonal antibody anti‐calcitonin gene‐related peptide (CGRP) ligand, can reduce caregivers' distress and improve their mutuality with patients. BACKGROUND: Migraine is a highly disabling chronic dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fofi, Luisa, Altamura, Claudia, Fiorentini, Giulia, Brunelli, Nicoletta, Marcosano, Marilena, Barbanti, Piero, Vernieri, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828231/ https://www.ncbi.nlm.nih.gov/pubmed/36205100 http://dx.doi.org/10.1111/head.14400

Ejemplares similares

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

Gepants — a long way to cure: a narrative review
por: Altamura, Claudia, et al.
Publicado: (2022)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study
por: Altamura, Claudia, et al.
Publicado: (2023)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
por: Altamura, Claudia, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles—A Narrative Review
por: Bonura, Adriano, et al.
Publicado: (2023)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
por: Nichols, Russell, et al.
Publicado: (2018)

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
por: Kudrow, David, et al.
Publicado: (2022)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials
por: Ailani, Jessica, et al.
Publicado: (2022)

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
por: Rosen, Noah, et al.
Publicado: (2018)

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies
por: Smitherman, Todd A., et al.
Publicado: (2020)

Stroke territory and atherosclerosis in ischemic stroke patients with a history of migraine with aura
por: Altamura, Claudia, et al.
Publicado: (2023)

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
por: Kudrow, David, et al.
Publicado: (2020)

Cerebral Hemodynamics, Right-to-Left Shunt and White Matter Hyperintensities in Patients with Migraine with Aura, Young Stroke Patients and Controls
por: Brunelli, Nicoletta, et al.
Publicado: (2022)

Galcanezumab for migraine
Publicado: (2020)

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
por: Lipton, Richard B., et al.
Publicado: (2021)

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Carotid Artery Plaque Progression: Proposal of a New Predictive Score and Role of Carotid Intima-Media Thickness
por: Brunelli, Nicoletta, et al.
Publicado: (2022)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

Characterization of Familial and Sporadic Migraine
por: Ravn, Julie, et al.
Publicado: (2019)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

A Qualitative Study to Assess the Content Validity of the 24‐Hour Migraine Quality of Life Questionnaire in Patients with Migraine
por: Speck, Rebecca M., et al.
Publicado: (2020)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2019)

Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype
por: Nagaraj, Karthik, et al.
Publicado: (2022)

United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey
por: Gibbs, Sarah N., et al.
Publicado: (2020)

Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study
por: Altamura, Claudia, et al.
Publicado: (2020)

The migraine signature study: Methods and baseline results
por: Pressman, Alice R., et al.
Publicado: (2020)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ)
por: Hareendran, Asha, et al.
Publicado: (2018)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English‐speaking countries
por: Vives‐Mestres, Marina, et al.
Publicado: (2022)

Migraine Genetic Variants Influence Cerebral Blood Flow
por: Knol, Maria J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ofupf8bg30oe5bj6t8t5c0djlj